Clinical Trials Browser

Has announcements × Peritoneal Neoplasms × relacorilant × Clear all

NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Phase 3 Active not recruiting

381 enrolled 1 FDA

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms